BCR and chronic myelogenous leukemia, BCR-ABL1 positive: As such, it would be interesting to conduct bacterial challenge assays examining the JAK/STAT pathway, which might elucidate the etiology behind resistance to TKI treatment experienced by CML patients with mutant BCR-ABLT315Iand whether this strong stress response perpetuated by the JAK-STAT pathway may result in suppression of other critical immune pathways which might affect response to treatment.